Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)18.82bn
- Net income in MXN2.22bn
- Incorporated1996
- Employees1.62k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frontier Biotechnologies Inc | 348.12m | -496.22m | 20.08bn | 302.00 | -- | 7.00 | -- | 57.67 | -0.5067 | -0.5067 | 0.3555 | 2.93 | 0.07 | 1.83 | 3.11 | 440,903.90 | -9.97 | -12.65 | -12.47 | -14.50 | 30.86 | 18.59 | -142.54 | -333.96 | 2.61 | -- | 0.2596 | -- | 13.32 | 44.07 | 38.78 | -- | -35.01 | -- |
| Wuhan Keqian Biology Co Ltd | 2.57bn | 1.05bn | 20.17bn | 924.00 | 19.22 | 1.90 | -- | 7.85 | 0.8613 | 0.8613 | 2.10 | 8.72 | 0.2122 | 2.69 | 3.34 | 1,062,969.00 | 8.69 | 11.71 | 9.89 | 13.56 | 63.02 | 73.57 | 40.95 | 44.51 | 5.07 | -- | 0.0147 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 3.50bn | 585.15m | 20.26bn | 1.52k | 34.50 | 2.80 | -- | 5.78 | 1.27 | 1.27 | 7.62 | 15.65 | 0.3922 | 1.85 | 7.91 | 880,686.90 | 6.55 | 8.09 | 8.03 | 9.82 | 73.23 | 81.72 | 16.70 | 20.10 | 3.01 | -- | 0.0592 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| BioGaia AB | 2.73bn | 596.28m | 20.48bn | 224.00 | 35.24 | 6.14 | 32.19 | 7.50 | 3.06 | 3.06 | 14.04 | 17.59 | 0.629 | -- | -- | 6,307,498.00 | 13.73 | 14.76 | 14.90 | 16.03 | 72.81 | 73.06 | 21.83 | 27.38 | -- | -- | 0.00 | 129.54 | 9.73 | 13.11 | -3.82 | 13.40 | -18.36 | 33.95 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 2.09bn | 558.21m | 20.49bn | 1.22k | 36.42 | 3.30 | -- | 9.79 | 0.2592 | 0.2592 | 0.9575 | 2.86 | 0.2598 | 1.06 | 2.59 | 657,104.30 | 6.93 | 8.91 | 9.07 | 12.10 | 53.92 | 53.44 | 26.66 | 27.68 | 2.03 | -- | 0.1591 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Genomma Lab Internacional SAB de CV | 18.82bn | 2.22bn | 20.61bn | 1.62k | 9.05 | 1.81 | 7.98 | 1.10 | 2.28 | 1.72 | 19.10 | 11.39 | 0.829 | 3.28 | 3.78 | 11,723,310.00 | 9.77 | 6.85 | 14.73 | 10.26 | 63.56 | 61.94 | 11.79 | 8.93 | 1.29 | 8.14 | 0.3883 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
| Vetoquinol SA | 11.74bn | 1.28bn | 20.73bn | 2.50k | 16.09 | 1.64 | 11.47 | 1.77 | 4.98 | 4.98 | 45.71 | 48.80 | 0.7508 | 2.46 | 5.56 | 215,592.20 | 8.17 | 7.52 | 10.16 | 9.96 | 50.82 | 61.63 | 10.88 | 9.54 | 2.18 | -- | 0.0354 | 16.72 | 1.88 | 6.37 | 5.62 | 15.47 | 4.29 | 18.56 |
| Towa Pharmaceutical Co Ltd | 32.81bn | 2.40bn | 20.83bn | 4.79k | 8.30 | 0.9179 | 4.22 | 0.635 | 385.70 | 385.70 | 5,273.63 | 3,486.39 | 0.5759 | 1.57 | 3.69 | 54,217,630.00 | 4.21 | 3.89 | 5.18 | 5.07 | 36.49 | 37.81 | 7.31 | 6.61 | 1.58 | -- | 0.5737 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Beijing Konruns Pharmaceutical Co Ltd | 2.19bn | 117.81m | 20.84bn | 668.00 | 180.34 | 2.53 | -- | 9.51 | 0.2774 | 0.2774 | 5.37 | 19.79 | 0.2156 | 1.55 | 3.01 | 1,254,736.00 | 0.587 | 3.82 | 0.6987 | 4.45 | 89.12 | 88.68 | 2.72 | 16.16 | 3.59 | -- | 0.0618 | 31.72 | -10.28 | -4.99 | -71.94 | -30.80 | 40.67 | -- |
| Procter & Gamble Health Ltd | 2.66bn | 548.36m | 21.29bn | 1.34k | 38.82 | 18.16 | 35.45 | 8.00 | 151.32 | 151.32 | 733.65 | 323.48 | -- | -- | -- | 9,117,141.00 | -- | -- | -- | -- | 71.95 | -- | 20.62 | -- | 1.94 | 544.11 | 0.014 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
Data as of Jul 18 2025. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
20.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 May 2025 | 39.21m | 3.92% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 28.15m | 2.82% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 23.17m | 2.32% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 03 Jul 2025 | 20.17m | 2.02% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 19.37m | 1.94% |
| Swedbank Robur Fonder ABas of 30 May 2025 | 19.26m | 1.93% |
| Skagen ASas of 30 Apr 2025 | 17.93m | 1.79% |
| Wellington Management Co. LLPas of 31 May 2025 | 13.92m | 1.39% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 13.92m | 1.39% |
| North of South Capital LLPas of 31 Dec 2024 | 13.69m | 1.37% |
More ▼
Data from 31 Dec 2024 - 10 Jul 2025Source: FactSet Research Systems Inc.
